Compare Natera Inc. Common Stock (NTRA) vs Virtu Financial Inc. Class A Common Stock (VIRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Virtu Financial Inc. Class A Common Stock — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Virtu Financial Inc. Class A Common Stock trades at $55.56 (market cap $4.94B). The key difference: Natera Inc. Common Stock is far larger — about 11.5× Virtu Financial Inc. Class A Common Stock's market cap, and Virtu Financial Inc. Class A Common Stock pays a 1.72% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Virtu Financial Inc. Class A Common Stock for 6 Days on average.
| NTRA | VIRT | |
|---|---|---|
Market Cap | $57.03B | $4.94B |
Volume | 1,131,157 | 1,546,091 |
Sector | Health | Financials |
52-Week High | $425.64 | $67.93 |
52-Week Low | $179.42 | $32.53 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $56.18B | $14.65B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VIRT trades at $55.94, down 1.46% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 9.29, net income margin of 13.5%, and ROE of 31.65%. Recent expansion into Saudi Exchange block trading and consistent earnings outperformance support growth prospects. Analyst consensus price target is $63.00 with mixed ratings (38% buy, 46% hold).
VIRT presents a value opportunity with attractive valuation metrics and strong profitability, though technical indicators suggest near-term pressure. The company's market-making business demonstrates resilience with improving cash flow trends. Key risks include market volatility sensitivity and competitive pressures in financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Virtu Financial Inc. Class A Common Stock
Virtu Financial provides technology-enabled market-making and execution services. Its platforms help institutional, retail, and other market participants trade across global financial markets.
Read more on VIRT →
